FDA greenlights Lumos Labs’ digital ADHD therapeutic
December 11, 2025
Lumos Labs’ LumosityRx is positioned for use alongside other ADHD treatment modalities such as medication and therapy.
Lumos Labs’ LumosityRx is positioned for use alongside other ADHD treatment modalities such as medication and therapy.
Ceribell (Nasdaq:CBLL) announced that it received FDA 510(k) clearance for its proprietary delirium monitoring solution.
HeartBeam (Nasdaq:BEAT) announced today that it received FDA 510(k) clearance for its 12-lead electrocardiogram (ECG) synthesis software.
Intuitive (NASDAQ: ISRG)+
announced today that the FDA cleared its da Vinci single port (SP) surgical robot for use in new types of procedures.
HeartBeam’s ECG software duplicates the 12-lead ECG approach undertaken in healthcare settings with electrodes to evaluate heart arrhythmias.
The assay is currently available in nations that recognise the CE Mark.
The ProVee System is a next-generation prostatic urethral stent designed to gently open up the obstructed prostate and relieve lower urinary tract symptoms associated with BPH
Medical Microinstruments (MMI) announced today that the FDA granted 510(k) clearance for its NanoWrist surgical robot instruments.
The approval is said to cover a range of clinical indications and supports use in both acute and chronic patients.
Resmed (NYSE: RMD)+
announced today that it received FDA clearance for its Smart Comfort personalized therapy offering.